Hope Women's Cancer Centers-Asheville
Hope Women's Cancer Centers-Asheville
Asheville, North Carolina, United States21 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone | Adnexal Diseases, Carcinoma, Endometrioid, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, carcinosarcoma, endocrine system disorder, endometrial serous adenocarcinoma, endometrial undifferentiated carcinoma, endometrium adenocarcinoma, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, mixed neoplasm, neoplasm, ovarian cancer, ovarian disorder, sarcoma | Active, not recruiting | Phase 2 | 2026-10-01 | NCT03660826 | |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, ovarian seromucinous carcinoma | Active, not recruiting | Phase 2 / Phase 3 | 2026-10-01 | NCT02839707 | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Adnexal Diseases, Blood Protein Disorders, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, benign urinary system neoplasm, breast carcinoma, breast disorder, breast neoplasm, carcinoma, carcinoma of esophagus, cardiovascular disorder, cervical carcinoma, cervix disorder, colon carcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrial carcinoma, endometrium neoplasm, epithelial neoplasm, esophageal disorder, exocrine pancreatic carcinoma, female reproductive system disorder, female reproductive system neoplasm, gastric carcinoma, gastric neoplasm, glioma, gonadal disorder, head and neck carcinoma, hematologic disorder, hematopoietic and lymphoid cell neoplasm, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, hepatocellular carcinoma, immune system disorder, immunoproliferative disorder, intestinal disorder, kidney cancer, kidney disorder, liver disorder, lung carcinoma, lung disorder, lung neoplasm, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, monoclonal gammopathy, neoplasm, neuroendocrine neoplasm, neuroepithelial neoplasm, ovarian cancer, ovarian carcinoma, ovarian disorder, pancreas disorder, pancreatic neoplasm, plasma cell neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate carcinoma, prostate disorder, rectal carcinoma, rectal disorder, rectal neoplasm, renal carcinoma, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin carcinoma, skin disorder, skin neoplasm, stomach disorder, thyroid gland carcinoma, thyroid gland disorder, thyroid tumor, urinary bladder carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine cancer, uterine disorder, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-10-01 | NCT02465060 | |
| Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic | Neoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT02115282 | |
| Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-10-01 | NCT01886872 | |
| Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 3 | 2026-10-01 | NCT01274338 | |
| Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | Neoplasms by Histologic Type, Neoplasms, Ductal, Lobular, and Medullary, adenocarcinoma, breast carcinoma in situ, carcinoma, ductal breast carcinoma in situ, epithelial neoplasm, in situ carcinoma, invasive breast carcinoma, neoplasm, synchronous bilateral breast carcinoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT01272037 | |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | breast adenocarcinoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT00433511 | |
| Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT00310180 | |
| Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, inflammatory breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-09-29 | NCT03598257 | |
| Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | endometrial adenosquamous carcinoma, endometrial clear cell adenocarcinoma, endometrial serous adenocarcinoma, endometrium adenocarcinoma | Active, not recruiting | Phase 2 | 2026-09-09 | NCT00977574 | |
| Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, breast carcinoma in situ, breast disorder, breast neoplasm, carcinoma, epithelial neoplasm, in situ carcinoma, invasive breast carcinoma, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-08-31 | NCT02954874 | |
| Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-08-31 | NCT01901094 | |
| A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian carcinoma, ovarian disorder | Recruiting | Not applicable | 2026-08-07 | NCT04251052 | |
| Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, endometrium neoplasm, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, uterine disorder | Active, not recruiting | Phase 2 | 2026-08-04 | NCT05554328 | |
| Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-07-01 | NCT03488693 | |
| Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Adnexal Diseases, Brenner tumor, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Urogenital Diseases, Urogenital Neoplasms, connective tissue neoplasm, endocrine system disorder, epithelial neoplasm, fallopian tube disorder, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube neoplasm, fallopian tube transitional cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, fibroepithelial neoplasm, gonadal disorder, neoplasm, ovarian Brenner tumor, ovarian cancer, ovarian clear cell malignant adenofibroma, ovarian disorder, ovarian endometrioid adenocarcinoma, ovarian mucinous adenocarcinoma, ovarian seromucinous carcinoma, ovarian serous adenocarcinoma, ovarian transitional cell carcinoma, primary peritoneal serous adenocarcinoma, undifferentiated ovarian carcinoma | Active, not recruiting | Phase 3 | 2026-05-29 | NCT01167712 | |
| Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-05-06 | NCT02488967 | |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-04-23 | NCT04852887 | |
| S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, male breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-02-10 | NCT01674140 | |
| MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ | Neoplasms by Histologic Type, Neoplasms, Ductal, Lobular, and Medullary, adenocarcinoma, breast carcinoma in situ, carcinoma, ductal breast carcinoma in situ, epithelial neoplasm, in situ carcinoma, neoplasm | Active, not recruiting | Not applicable | 2025-12-19 | NCT02352883 |